GlassScriptPhysician profile
Nicholas Vernetti
NPI 1407939317
$61,595.11
in general payments reported to CMS, 2019-2025
51 companies · $12K in 2025
The $12K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $7,295 · 2021: $1,263 · 2022: $975 · 2023: $1,416 · 2024: $13K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $4,685 · Consulting Fee: $3,200 · Travel and Lodging: $2,492 · Education: $57.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,340.25 |
| Food and Beverage | $4,684.97 |
| Consulting Fee | $3,200.00 |
| Travel and Lodging | $2,492.49 |
| Education | $57.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30,919.66 | 2019-2025 | Evenity, Tepezza, Prolia |
| Lilly USA, LLC | $10,015.68 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,530.42 | 2021-2025 | Jardiance |
| Neurocrine Biosciences, INC. | $4,224.45 | 2025 | |
| Novo Nordisk INC | $1,990.49 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Eli Lilly and Company | $1,387.52 | 2019 | |
| Abbott Laboratories | $875.51 | 2019-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $486.53 | 2020-2025 | Korlym |
| Tandem Diabetes Care, INC. | $423.96 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $370.23 | 2019-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $338.44 | 2019-2022 | |
| Mannkind Corporation | $316.10 | 2019-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $315.19 | 2019-2024 | |
| Abbvie INC. | $228.90 | 2020-2025 | Synthroid |
| Amarin Pharma, INC. | $176.67 | 2019-2021 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $169.87 | 2024-2025 | Mycapssa, Myalept |
| Horizon Therapeutics Plc | $139.12 | 2019-2023 | Tepezza |
| Beta Bionics, INC. | $133.05 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ultragenyx Pharmaceutical INC. | $131.70 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $125.32 | 2022-2024 | Recorlev |
| Medtronic Minimed, INC. | $110.85 | 2020 | |
| Shire North American Group INC | $95.44 | 2019 | |
| Lifescan, INC. | $95.23 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $89.28 | 2023-2025 | |
| Ascendis Pharma Endocrinology INC | $78.61 | 2024-2025 | Yorvipath, Skytrofa |
| Radius Health, INC. | $77.96 | 2020-2025 | Tymlos |
| Recordati_rare_diseases_inc. | $73.85 | 2023-2025 | Isturisa, Signifor Lar |
| Ascensia Diabetes Care US INC. | $68.40 | 2022-2025 | |
| Amryt Pharma Holdings LTD | $64.47 | 2020-2022 | |
| Madrigal Pharmaceuticals | $46.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Becton, Dickinson and Company | $38.55 | 2020 | |
| Nevro Corp. | $33.32 | 2023 | Senza |
| Insulet Corporation | $32.18 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $31.30 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.57 | 2023 | |
| Janssen Pharmaceuticals, INC | $29.56 | 2020 | |
| Boston Scientific Corporation | $27.52 | 2025 | General - Pain Management |
| Soleno Therapeutics, INC. | $25.37 | 2025 | Vykat Xr |
| Antares Pharma, INC. | $24.71 | 2019-2020 | |
| Kyowa Kirin, INC. | $23.64 | 2023 | Crysvita |
| Sequel Med Tech, LLC | $22.62 | 2025 | Twiist |
| Embecta Corp. | $21.60 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Eisai INC. | $21.21 | 2019 | |
| Zealand Pharma US, INC. | $19.33 | 2022 | |
| Pfizer INC. | $19.12 | 2023 | |
| Companion Medical, INC. | $17.99 | 2020 | |
| Ibsa Pharma INC. | $17.85 | 2023 | Tirosint, Licart |
| Almatica Pharma LLC | $17.00 | 2025 | Teriparatide |
| Esperion Therapeutics, INC. | $15.33 | 2020 | |
| Medtronic, INC. | $13.80 | 2025 | Minimed 780g |
| Halozyme INC | $13.17 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Vernetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.